Načítá se...
ATRT-38. TAK228 COMBINES WITH NAVITOCLAX TO ENHANCE PLATINUM-INDUCED CYTOTOXICITY IN AT/RT
Survival in atypical teratoid rhabdoid tumors (AT/RT) is plagued by drug resistance to platinum-intensive therapies. We have previously shown the dual mTORC1/2 inhibitor TAK228 (aka MLN0128) extends survival in orthotopic mouse models of AT/RT by enhancing cisplatin-induced apoptosis. TAK228 decreas...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6012780/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.035 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|